Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial 3.0 mg, 3 times daily selected as dose for future c

Achieve Life Sciences Announces Statistically Significant

Improvement in Quit Rates for Simplified Cytisinicline Dosing

Schedule in Phase 2b ORCA-1 Dose-Selection Trial

3.0 mg, 3 times daily selected as dose for future clinical development

SEATTLE, Wash. and VANCOUVER, British Columbia, June 11, 2019 Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage

pharmaceutical company focused on nicotine addiction, today announced positive results from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation. The outcome of the 254-subject, ORCA-1 trial is the selection of 3.0 mg, three times daily (TID) for Phase 3 development.

The primary endpoint was the reduction in daily smoking, a self-reported measure. Three of the four cytisinicline treatment arms demonstrated a statistically

significant improvement, as defined in the protocol as p < 0.05, compared to placebo. The fourth arm trended to significance (p= 0.052). Across all treatment arms, over the 25-day treatment period, subjects

on cytisinicline experienced a 74-80% median reduction in the number of cigarettes smoked, compared to a 62% reduction in the placebo arms.

The secondary endpoint of the trial was a 4-week continuous abstinence rate, which is the relevant endpoint for

regulatory approval. Cytisinicline treatment showed significant improvements in abstinence rates compared to placebo. The most impressive results were observed in the 3 mg TID treatment arm which demonstrated a 54% abstinence rate at

week 4, compared to 16% for placebo (p < 0.0001) and a continuous abstinence rate, weeks 5 through 8, of 30% for cytisinicline compared to 8% for placebo (p= 0.005).

All four cytisinicline arms demonstrated statistically significant (p < 0.05) reductions in expired carbon monoxide (CO), a biochemical measure of smoking

activity. Expired CO levels declined by a median of 71-80% in the cytisinicline treatment arms, compared to only 38% in the placebo arms. The lack of consistency in the reduction of expired CO levels compared

to the self-reported data suggest potential under-reporting of cigarettes smoked by subjects on placebo.

The robust efficacy results in the

simplified, three times daily dosing arms exceeded our expectations, particularly, the statistically significant abstinence rates. This is of importance given that a continuous abstinence rate is the endpoint for regulatory approval in smoking

cessation trials, said Rick Stewart, Chairman and CEO of Achieve. In addition to efficacy, the cytisinicline safety data observed in ORCA-1 reflects the historically strong safety profile already

experienced in Central and Eastern Europe.

Adherence to study treatment was greater than 98.5% across all arms and cytisinicline was well-tolerated

with no serious adverse events reported. The most commonly reported (>5%) adverse events (AEs) across all cytisinicline treatment arms versus placebo were abnormal dreams, insomnia, upper respiratory tract infections, and nausea. In the 3 mg TID

treatment arm versus placebo, the most common AEs were abnormal dreams, insomnia, and constipation (each 6% vs 2%), upper respiratory tract infections (6% vs 14%), and nausea (6% vs 10%).

The Company expects to conduct further analyses of the ORCA-1 trial

and submit data for presentation at a future medical meeting. Additionally, Achieve plans to discuss the trial s outcome with the FDA and finalize Phase 3 protocol details in the second-half of 2019.

Achieve would like to thank the investigators, healthcare providers, and subjects whose commitment and efforts to

ORCA-1 made this trial a success. Additional information on cytisinicline and the ORCA program can be found at www.achievelifesciences.com and www.orcaprogram.com.

Conference Call Details

Achieve will host a conference

call at 8:30 a.m. Eastern time today, Tuesday, June 11, 2019. To access the webcast, log on to the investor relations page of the Achieve website at

http://ir.achievelifesciences.com/events-and-webcasts. Alternatively, access to the live conference call is available by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 6986745. A webcast replay will be available approximately two hours after the call

and will be archived on the website for 90 days.

Tobacco use is currently the leading cause of preventable death and is responsible for nearly seven million deaths annually worldwide1. It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking2. Achieve s focus is to address the global

smoking health epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding

affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction

associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over

20 million people have used cytisinicline to help combat nicotine addiction.

ORCA-1 is the first in Achieve s ORCA (Ongoing Research of Cytisinicline for

Addiction) Program, which aims to evaluate the safety and effectiveness of cytisinicline for smoking cessation and potentially other addiction indications. The study was designed to evaluate the declining titration schedule, currently

utilized in Central and Eastern Europe, compared to a simplified TID schedule at both the 1.5 mg and 3 mg cytisinicline doses compared to placebo. Subjects were provided

face-to-face behavioral support over the full course of the study. Smoking abstinence was measured at week 4 (end-of-treatment). Continuous abstinence was also measured at weeks 5 through 8 (end-of-study). Abstinence assessments were

verified by expired carbon monoxide (CO), a biochemical measure of smoking activity.

The study was blinded to dosing. Demographics were similar between

schedules and for treatment arms in gender, age, years of prior smoking, and number of previous quit attempts. At baseline, subjects in the study reported smoking a median of 20 cigarettes per day. ORCA-1 was

initiated in October 2018 and enrolled 254 smokers at eight centers across the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform

Act of 1995, including, but not limited to, statements regarding the planned cytisinicline clinical development activities, the timing of clinical development activities related to cytisinicline, the potential market size for cytisinicline and the

potential benefits of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner,

if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management s current expectations and beliefs and are subject to a number of

risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected

benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new

developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve s intellectual property may not be adequately protected; general business and economic conditions; and the

other factors described in the risk factors set forth in Achieve s filings with the Securities and Exchange Commission from time to time, including Achieve s Annual Reports on Form 10-K and Quarterly

Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be

required by applicable law.

(415) 375-3340 ext. 4

ORCA is a trademark of Achieve Life Sciences, Inc.